Pacific Edge reviews US pricing for new Cxbladder test, trading halted

Pacific Edge reviews US pricing for new Cxbladder test, trading halted
Pacific Edge says Cxbladder Triage Plus delivers “significant performance improvements” compared to its existing tests. (Image: Pacific Edge)
Rebecca Howard
Pacific Edge has been placed on a trade halt while it reviews draft gapfill or reimbursement rates for its new Cxbladder Triage Plus test from the US Centres for Medicare and Medicaid Services.“[It said it's] reviewing the prices and the associated documentation and needs time to assess the implications of them, consult with its advisers and industry partners, and prepare an announcement that provides context to investors.”Gapfill prices are proposed reimbursement rates for new or unpriced clinical diagnostic laboratory tests.Th...

More Markets

NZ sharemarket starts new week up 0.2%
Markets Market Close

NZ sharemarket starts new week up 0.2%

The S&P/NZX 50 Index closed at 13,499.04, up 34.58 points or 0.26%.

Graham Skellern 17 Nov 2025
The Warehouse CEO Mark Stirton unveils cost reset amid margin pressure
Retail

The Warehouse CEO Mark Stirton unveils cost reset amid margin pressure

Continued margin pressure and an unsustainable cost base have led The Warehouse Group to implement a comprehensive cost reset programme, something which could see head office roles slashed to save costs.Chief executive Mark Stirton said the group’s shareholders expect decisive ac...

Staff reporters 17 Nov 2025
Banks accelerate crackdown on ‘mule’ scammers
Finance

Banks accelerate crackdown on ‘mule’ scammers

New technology picks up crooked “muleteers” more quickly.

Andy Macdonald 17 Nov 2025